Brief: Chemomab Announces Multiple Presentations at AASLD The Liver Meeting 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
06/11/2025 13:50
Nov 6 (Reuters) - Chemomab Therapeutics Ltd CMMB.O: CHEMOMAB ANNOUNCES MULTIPLE PRESENTATIONS AT AASLD THE LIVER MEETING® 2025 FEATURING CLINICAL DATA FROM THE NEBOKITUG PHASE 2 TRIAL IN PRIMARY SCLEROSING CHOLANGITIS Source text: ID:nGNX1xgcZd Further company coverage: CMMB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update